Chugai Pharmaceutical Co (4519) Price & Analysis

Compare

1 Followers

4519 Stock Chart & Stats

Day’s Range― - ―

52-Week Range¥4,572.00 - ¥8,655.00

Previous CloseN/A

Volume1.90M

Average Volume (3M)2.63M

Market Cap

¥12.43T

Enterprise ValueN/A

Total Cash (Recent Filing)¥944.55B

Total Debt (Recent Filing)¥13.09B

Price to Earnings (P/E)30.3

Beta1.01

Next Earnings

Jul 24, 2025

EPS Estimate

64.69

Next Dividend Ex-Date

Jun 27, 2025

Dividend Yield1.18%

Share Statistics

EPS (TTM)59.09

Shares Outstanding1,679,057,600

10 Day Avg. Volume2,421,830

30 Day Avg. Volume2,632,663

Financial Highlights & Ratios

PEG Ratio5.87

Price to Book (P/B)7.44

Price to Sales (P/S)0.00

P/FCF Ratio40.16

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥8,400.34

Price Target Upside11.12% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Chugai Pharmaceutical Co News

PremiumCompany Announcements

Chugai Pharmaceutical Reports Strong Q1 2025 Performance

1M ago

PremiumCompany Announcements

Chugai Pharmaceutical Reports Strong Q1 2025 Results and Announces Special Dividend

1M ago

PremiumPre-Earnings

Chugai Pharmaceutical Co (CHGCF) Q1 Earnings Cheat Sheet

1M ago

PremiumCompany Announcements

Chugai Pharmaceutical Adjusts Treasury Share Disposal Plan

1M ago

PremiumCompany Announcements

Chugai Highlights Eli Lilly’s Promising Phase 3 Results for Orforglipron

1M ago

PremiumCompany Announcements

Chugai Pharmaceutical Considers Investment Unit Reduction

2M ago

PremiumCompany Announcements

Chugai Pharmaceutical Announces Disposal of Treasury Shares for Compensation Plan

2M ago

PremiumCompany Announcements

Chugai Pharmaceutical’s Earnings Call: Record Performance Amid Challenges

4M ago

See All JP:4519 News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

4.32%

Mutual Funds

0.08% Other Institutional Investors

91.40% Public Companies and

Individual Investors

Detailed Ownership Overview >

4519 FAQ

What was Chugai Pharmaceutical Co ’s price range in the past 12 months?

Chugai Pharmaceutical Co lowest stock price was ¥4572.00 and its highest was ¥8655.00 in the past 12 months.

What is Chugai Pharmaceutical Co ’s market cap?

Chugai Pharmaceutical Co ’s market cap is ¥12.43T.

When is Chugai Pharmaceutical Co ’s upcoming earnings report date?

Chugai Pharmaceutical Co ’s upcoming earnings report date is Jul 24, 2025 which is in 60 days.

How were Chugai Pharmaceutical Co ’s earnings last quarter?

Chugai Pharmaceutical Co released its earnings results on Apr 24, 2025. The company reported ¥59.09 earnings per share for the quarter, beating the consensus estimate of ¥50.968 by ¥8.122.

Is Chugai Pharmaceutical Co overvalued?

According to Wall Street analysts Chugai Pharmaceutical Co ’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Chugai Pharmaceutical Co pay dividends?

Chugai Pharmaceutical Co pays a Annually dividend of ¥75 which represents an annual dividend yield of 1.18%. See more information on Chugai Pharmaceutical Co dividends here

What is Chugai Pharmaceutical Co ’s EPS estimate?

Chugai Pharmaceutical Co ’s EPS estimate is 64.69.

How many shares outstanding does Chugai Pharmaceutical Co have?

Chugai Pharmaceutical Co has 1,679,057,600 shares outstanding.

What happened to Chugai Pharmaceutical Co ’s price movement after its last earnings report?

Chugai Pharmaceutical Co reported an EPS of ¥59.09 in its last earnings report, beating expectations of ¥50.968. Following the earnings report the stock price went up 0.696%.

Which hedge fund is a major shareholder of Chugai Pharmaceutical Co ?

Currently, no hedge funds are holding shares in JP:4519

Company Description

Chugai Pharmaceutical Co

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

4519 Company Deck

4519 Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted record-breaking financial results and significant overseas sales growth, coupled with an increase in dividends, showcasing the company's strong performance. However, challenges such as the decline in domestic sales, project discontinuations, and potential biosimilar competition were noted.Read More>

4519 Stock 12 Month Forecast

Average Price Target

¥8,400.34

▲( 11.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4989":"¥4,989","5842":"¥5,842","6695":"¥6,695","7548":"¥7,548","8401":"¥8,401"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8400.3421728312,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥8K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8400.3421728312,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥8K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8400.3421728312,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥8K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4989,5842,6695,7548,8401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Nov<br/>2024","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6788,6912.026320987015,7036.052641974031,7160.078962961046,7284.105283948062,7408.131604935077,7532.1579259220925,7656.184246909108,7780.210567896123,7904.236888883139,8028.263209870154,8152.28953085717,8276.315851844185,{"y":8400.3421728312,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6788,6912.026320987015,7036.052641974031,7160.078962961046,7284.105283948062,7408.131604935077,7532.1579259220925,7656.184246909108,7780.210567896123,7904.236888883139,8028.263209870154,8152.28953085717,8276.315851844185,{"y":8400.3421728312,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6788,6912.026320987015,7036.052641974031,7160.078962961046,7284.105283948062,7408.131604935077,7532.1579259220925,7656.184246909108,7780.210567896123,7904.236888883139,8028.263209870154,8152.28953085717,8276.315851844185,{"y":8400.3421728312,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5272.541,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6065.905,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5653.832,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4990.544,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4990.544,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5648,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6480,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6936,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7074,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7213,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6605,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6999,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6788,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >